Lapatinib Teva (Lapatinib)

Lapatinib blocks the intracellular tyrosine kinase activity of EGFR (ErbB1) and HER2 (ErbB2). This inhibition prevents activation of downstream pathways such as MAPK and PI3K/AKT, which are essential for cancer cell proliferation and survival, thereby slowing disease progression.

The specific dose and schedule of Lapatinib Teva are determined by the treating physician based on the patient’s clinical condition, concomitant therapies, and tolerability. Prescribers follow approved labeling and clinical guidelines to individualise therapy.

Safety data for Lapatinib in pregnancy and lactation are limited. It should only be used if the potential benefit outweighs the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional after thorough counseling.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lapatinib is a small‑molecule tyrosine kinase inhibitor that can be taken orally, whereas agents like trastuzumab and pertuzumab are monoclonal antibodies administered intravenously. Lapatinib offers the advantage of oral dosing and can be combined with certain chemotherapies, but its safety profile and efficacy differ, requiring individualized treatment decisions.

Lapatinib Teva should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and excessive heat to maintain stability.

Lapatinib Teva is taken orally, usually once daily, with or without food as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not chewed or crushed.

Serious risks include hepatotoxicity, severe skin reactions such as Stevens‑Johnson syndrome, QT interval prolongation leading to cardiac arrhythmias, interstitial lung disease, and significant diarrhea that can cause dehydration. Patients should be monitored closely for these events.

Lapatinib is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. Caution is advised for individuals with pre‑existing severe cardiac disease, uncontrolled liver dysfunction, or those taking strong CYP3A4 inhibitors without appropriate dose adjustments.